MBX Biosciences (MBX) EBIT (2023 - 2026)

MBX Biosciences has disclosed EBIT across 4 years of filings, most recently posting -$27.3 million for Q1 2026.

• EBIT for Q1 2026 came in at -$27.3 million, down 2.77% year-over-year; the trailing twelve-month figure through Mar 2026 was -$98.8 million (down 21.35% YoY), and the FY2025 annual result was -$98.1 million, down 43.79% from the prior year.
• EBIT came in at -$27.3 million for Q1 2026 at MBX Biosciences, down from -$25.8 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$10.0 million in Q4 2023 to a low of -$27.3 million in Q1 2026.
• The 4-year median for EBIT is -$19.6 million (2024), against an average of -$19.5 million.
• Across the five-year window, EBIT tumbled 99.26% in 2025 and slipped 2.77% in 2026, its largest moves.
• MBX Biosciences' EBIT stood at -$10.0 million in 2023, then plunged by 86.27% to -$18.6 million in 2024, then plunged by 38.61% to -$25.8 million in 2025, then slipped by 5.7% to -$27.3 million in 2026.
• The last three EBIT figures came in at -$27.3 million (Q1 2026), -$25.8 million (Q4 2025), and -$23.9 million (Q3 2025), per Business Quant data.